



"Targeting interleukin-33 and thymic stromal lymphopoietin pathways for novel pulmonary therapeutics in asthma and COPD". Ariel A. Calderon, Colin Dimond, David F. Choy, Rajita Pappu, Michele A. Grimbaldeston, Divya Mohan and Kian Fan Chung. *Eur Respir Rev* 2023; 32: 220144

Copyright ©The authors 2023

This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org Fan Chung. Eur Respir Rev 2023; 32: 220144

The authors of this review, published in the March 2023 issue, requested to clarify the following sentence:

"In COPD, TSLP production in bronchial epithelial cells may be mediated by Th17, suggesting that anticholinergics may exert an anti-inflammatory effect in COPD *via* TSLP [111] and that the role of TSLP in COPD may be more limited to airway smooth muscles."

This has been corrected to read:

"In COPD, TSLP production in bronchial epithelial cells and involvement in releasing acetylcholine may be mediated by Th17, suggesting that anticholinergics may exert an anti-inflammatory effect in COPD *via* TSLP [111] and that the role of TSLP in COPD may be more limited to airway smooth muscles."


In addition, in table 1 the *Key results summary* for the entry *NCT03347279* [117] *NAVIGATOR study Tezepelumab* (anti-TSLP) has been corrected based on information presented in reference 117 in the review. The published table summary read:

"66% exacerbation rate reduction (p<0.001),  ${\rm FEV_1}$  improvement of 0.13 L (p<0.001) for 210 mg dose in comparison with placebo"

This has been corrected to:

"56% exacerbation rate reduction (p<0.001),  $FEV_1$  improvement of 0.13 L (p<0.001) for 210 mg dose in comparison with placebo"

Finally, a minor typographical error has been corrected in the first sentence of the section *Insights from clinical trials*. The sentence now reads:







The article has been corrected and republished online.